Preclinical is the bucket where peptide research lives between mechanism and the clinic. Coverage on this site has tracked rodent, pig, and non-human-primate readouts for compounds that are not yet in human trials but carry the strongest claims about the next generation of peptide therapeutics.
Lead programs covered here in 2026: the Lilly + Indiana Biosciences quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) with rodent data heading to ADA 2026 May 29, the DiMarchi/Tschöp/Müller GLP-1R/GIPR/PPARα/γ/δ peptide-drug conjugate published in Nature April 30, the BMC Biotechnology DualPep-ALO cell-penetrating peptide for hair growth, the Aivocode CAQK tetrapeptide for traumatic brain injury (EMBO Mol Med, October 2025), the UTHealth BLMP6 fibulin-4 peptide for metastatic triple-negative breast cancer, and the early atherosclerotic-plaque-prevention work with GLP-1.
Stories here cover animal-model efficacy, mechanism-of-action work, and IND-enabling readouts. See #animal-models, #mechanism, and #ind for adjacent threads.
Researchers at Kazan Federal University in Russia reported in Macromolecular Bioscience on October 21, 2026 a macroporous, multi-channel hydrogel scaffold made from oligo(poly(ethylene glycol) fumarate) and coated with four signaling peptides, IKVAV, RGD, GHK, and LRE, intended to bridge a completely severed spinal cord without added cells or growth factors. The peptide mix promoted nerve-cell growth in culture, and in a pilot study in minipigs with a cut spinal cord the implant integrated with tissue, kept its structure, and was infiltrated by host cells. The pilot looked at short-term integration, not recovery of movement.
Shandong University researchers reported in PLOS Biology on October 21, 2026 that mice lacking TIMD4, a macrophage protein elevated in colon tissue from people with ulcerative colitis, developed worse chemically induced colitis with more monocytes entering the colon. They designed a peptide from TIMD4's intracellular region, T4(365-378), and packaged it in macrophage-targeted nanoparticles, which reduced inflammatory signaling and eased colitis, performed similarly to a CCR2-blocking drug, and worked better combined with anti-α4β7 or anti-TNF antibodies than either treatment alone. The results are from mice and cells.
Researchers at the University of Rouen Normandy and Inserm reported in Frontiers in Pharmacology on October 21, 2026 that a single 10-nanogram injection into the brain's ventricles of OP, an analog of octadecaneuropeptide (ODN), a peptide made by astrocytes, prevented the loss of dopamine-producing neurons in mice given the toxin MPTP. The peptide reduced oxidative damage, lowered the inflammatory marker TNF-α while raising IL-10, and preserved tight-junction proteins of the blood-brain barrier, assessed seven days after the toxin. The work is in an acute mouse model, and the peptide was delivered directly into the brain.
Researchers from the Chinese Academy of Sciences and Southern Medical University reported in the Journal of Medicinal Chemistry on October 20, 2026 FAP-Man, a mannose-modified version of the FAP-2286 peptide scaffold that targets fibroblast activation protein, which is abundant in tumor-associated fibroblasts. In mice with U87MG tumors, the gallium-68 version reached 16.9% of the injected dose per gram of tumor at one hour versus 3.2% for gallium-68 FAP-2286, with better tumor-to-liver contrast, and lutetium-177 and actinium-225 versions slowed tumor growth compared with saline. The authors describe preliminary clinical PET scans as supportive but give no patient numbers in the abstract.
Researchers at Nanyang Technological University reported in ACS Nano on October 20, 2026 that peptides which separate into liquid droplets, called coacervates, can carry cargo into cells and release it when cathepsin B, an enzyme often overactive in cancer cells, cuts them. Standard cathepsin B cut sites borrowed from drug linkers worked poorly inside the dense droplets, but a newly designed four-amino-acid motif, FRFV, was cut efficiently and released cargo in cancer cells. The work is in the lab.
Researchers at Shanghai Ocean University reported in Molecules on October 19, 2026 that a carboxymethyl chitosan gel combined with hyaluronic acid and RGD, a short cell-adhesion peptide, curbed bacterial growth, reduced bleeding, and sped healing of full-thickness skin wounds in mice. Wound closure reached 95.56% by day 14 compared with 79.85% for the base gel, with denser collagen and lower inflammatory signals. The results are from mice.
Researchers at Kaohsiung Veterans General Hospital and National Sun Yat-sen University reported in Reproduction and Fertility on October 19, 2026 that MOTS-c, a small peptide encoded in mitochondrial DNA, increased mitochondrial mass and ATP-linked respiration in a model of aging human granulosa cells, the cells that support developing eggs, without raising oxidative stress. In eggs from aged mice treated outside the body, MOTS-c improved maturation and lowered oxidative-stress signals, though results stayed below those of young eggs. MOTS-c is sold online as a wellness peptide; this is cell and mouse work only.
Researchers at Hubei University of Medicine reported in Biomolecules on October 19, 2026 that SjAPI-2, a small peptide from scorpion venom, inhibited the classical complement pathway, part of the immune system that can damage the body's own tissue, by binding the complement proteins C4 and C4b. Mapping showed a loop between residues K30 and V38 does the work, and the peptide limited heart muscle damage in an ischemia-reperfusion injury model. The authors describe it as the first anti-complement peptide reported from scorpions; the work is preclinical.
Researchers at Nanjing University-affiliated hospitals reported in Cells on October 19, 2026 that tirzepatide improved ultrasound measures of strain on the lung circulation and reduced remodeling of small lung arteries in an animal model of pulmonary arterial hypertension. In lab experiments, the drug lowered lactate buildup in artery smooth muscle cells through the AMPK/SIRT1 pathway and reduced a histone mark that drives the cells' growth. The authors called it a preclinical rationale for testing tirzepatide in pulmonary hypertension.
Researchers at Shanghai Jiao Tong University reported in Nature Communications on October 17, 2026 a deep-learning model that designs antimicrobial lipopeptides, peptides with a fatty-acid tail, by accounting for how the tail changes activity. Starting from 2,657 bacterial peptide sequences mined from 96,911 genomes, the model screened 6,197 virtual lipopeptides; of 46 the team made, 44 killed bacteria, a 95.7% hit rate. The lead, LP630, worked against Gram-positive and Gram-negative bacteria and mycobacteria and treated infected wounds in mice.
Researchers at the Macau University of Science and Technology, with a co-author from drugmaker Livzon, reported in Advanced Science on October 18, 2026 a lipid depot loaded with VDAP, an anticancer peptide derived from an HIV protein, that changes its internal structure and releases the peptide faster in the acidic tissue left after tumor removal. In mice with incompletely removed breast tumors, the depot killed remaining tumor cells in a way that alerted the immune system, increased tumor-fighting T cells, and reduced regrowth and lung metastases. The work is in mice.
Weizmann Institute of Science researchers reported in the Journal of Medicinal Chemistry on October 17, 2026 that adding isopeptide bonds and fatty-acid tails to antimicrobial peptides produced lipo-isopeptides that resisted breakdown by protein-cutting enzymes and were most active against the yeast Candida albicans. The lead compound, C8-Amp1EP, was non-toxic in their tests, reduced fungal attachment and biofilm formation when coated on surfaces and cells, disrupted the fungal membrane, and was less likely than standard antifungal drugs to select for resistance during repeated exposure. The work is in the lab.
Researchers at Beijing University of Technology and the radiopharmaceutical company HTA reported in the Journal of Medicinal Chemistry on October 17, 2026 two gallium-68 cyclic peptide probes, WF1 and WF2, built to image carbonic anhydrase IX (CAIX), a marker of clear cell kidney cancer. Changing the peptide's ring-closing linker kept nanomolar binding to CAIX while sharply reducing binding to the related enzyme CAII, which made the earlier probe 68Ga-DPI-4452 accumulate in the digestive tract. In mice with kidney tumors, tumor uptake matched the older probe with less gut signal, and the probes bound human kidney cancer tissue samples; they have not been tested in patients.
Researchers at Shandong University and the Shandong Academy of Pharmaceutical Science reported in the Journal of Medicinal Chemistry on October 16, 2026 that they used a site-specific chemical ligation method to attach fatty acids of different lengths to teriparatide, the bone-building osteoporosis drug that must be injected daily. Of 12 lipidated versions, four matched native teriparatide's bone-building activity in lab and animal tests, and the lead compound, called 62, was markedly more stable in serum. The goal is a longer-acting osteoporosis injection; the work is preclinical.
University of Osaka surgeons, with co-authors from Japanese medical device maker Menicon, reported in Scientific Reports on October 15, 2026 a rat study of SPG-178, a self-assembling peptide hydrogel, to prevent pancreatic fistula, a leak of pancreatic fluid that often follows pancreas surgery. Three days after the pancreas was cut, fluid amylase, a marker of leakage, averaged 109 IU/L with SPG-178, compared with 283 in untreated rats and 219 with the standard polyglycolic acid mesh and fibrin glue, and the gel group had fewer adhesions and less tissue damage. Human testing has not been reported.
Researchers at the First Affiliated Hospital of Wenzhou Medical University reported in ACS Applied Materials & Interfaces on October 15, 2026 an injectable, biodegradable peptide hydrogel that slowly releases puerarin, an anti-scarring plant compound, inside the uterus. In rats with intrauterine adhesions, scar tissue that is a leading cause of infertility, the gel acted as a physical barrier, restored the uterine lining's glands and blood vessels, reduced fibrosis, and markedly raised pregnancy rates. The results are from rats.
Researchers at the Feinstein Institutes for Medical Research reported in Shock on October 13, 2026 that MOP3, a peptide derived from the protein MFG-E8 that tags the inflammatory signal eCIRP for removal by immune cells, reduced kidney damage when given as blood flow returned after 30 minutes of kidney ischemia in mice. Compared with untreated mice, MOP3 lowered circulating eCIRP by 40%, serum creatinine by 63%, blood urea nitrogen by 56%, and kidney injury markers such as KIM-1, and reduced tubular damage and cell death. The work is in mice.
Researchers at Fudan University reported in ACS Nano on October 13, 2026 a peptide-drug conjugate that links a two-part targeting peptide to luteolin, a plant compound, packaged in nanoparticles that release it in response to oxidative stress. Aimed at pericytes, the cells that support blood-brain barrier vessels, it reduced barrier leakage and immune-cell infiltration and promoted myelin repair in two mouse models of multiple sclerosis, and injection under the skin every other day raised brain exposure 2.65-fold and beat daily intravenous dosing. The results are from mice.